Sequestering sequestosome 1 via S-acylation in autophagy, Huntington disease, and beyond

Protein mislocalization and aggregation are hallmark features in neurodegeneration. As proteins mislocalize, proteostasis deficiency and protein aggregation typically follow. Autophagy is a crucial pathway for the removal of protein aggregates to maintain neuronal health, but is impaired in various...

Full description

Saved in:
Bibliographic Details
Main Authors: Y Alshehabi, F Abrar, D.D.O Martin
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Autophagy Reports
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/27694127.2025.2547975
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849224332730957824
author Y Alshehabi
F Abrar
D.D.O Martin
author_facet Y Alshehabi
F Abrar
D.D.O Martin
author_sort Y Alshehabi
collection DOAJ
description Protein mislocalization and aggregation are hallmark features in neurodegeneration. As proteins mislocalize, proteostasis deficiency and protein aggregation typically follow. Autophagy is a crucial pathway for the removal of protein aggregates to maintain neuronal health, but is impaired in various neurodegenerative diseases, including Huntington disease (HD). We identified S-acylation, a reversible lipid modification of proteins, as an important regulator in protein trafficking and autophagy. SQSTM1 (sequestosome 1/p62) is an essential selective autophagy receptor for the sequestration of ubiquitinated cargoes within autophagosomes and subsequent delivery into lysosomes for degradation. Recently, we reported that S-acylation of SQSTM1 at the di-cysteine motif C289,290 directs SQSTM1 to lysosomes. We further showed that SQSTM1 S-acylation is significantly reduced in brains from both HD patients and mouse HD model, which may result in the cargo sequestration defect within autophagosomes in HD. Treatment with palmostatin B, a deacylation inhibitor, significantly increases SQSTM1 localization to lysosomes. Our work highlights SQSTM1 S-acylation as a novel potential therapeutic strategy in HD. As a crucial autophagy component, our work suggests S-acylation of SQSTM1 may have a broader role in neurodegeneration.
format Article
id doaj-art-ef9dd5b54279478896fdda8a56ff5ceb
institution Kabale University
issn 2769-4127
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Autophagy Reports
spelling doaj-art-ef9dd5b54279478896fdda8a56ff5ceb2025-08-25T12:09:52ZengTaylor & Francis GroupAutophagy Reports2769-41272025-12-014110.1080/27694127.2025.2547975Sequestering sequestosome 1 via S-acylation in autophagy, Huntington disease, and beyondY Alshehabi0F Abrar1D.D.O Martin2Department of Biology, University of Waterloo, Waterloo, ON, CanadaDepartment of Biology, University of Waterloo, Waterloo, ON, CanadaDepartment of Biology, University of Waterloo, Waterloo, ON, CanadaProtein mislocalization and aggregation are hallmark features in neurodegeneration. As proteins mislocalize, proteostasis deficiency and protein aggregation typically follow. Autophagy is a crucial pathway for the removal of protein aggregates to maintain neuronal health, but is impaired in various neurodegenerative diseases, including Huntington disease (HD). We identified S-acylation, a reversible lipid modification of proteins, as an important regulator in protein trafficking and autophagy. SQSTM1 (sequestosome 1/p62) is an essential selective autophagy receptor for the sequestration of ubiquitinated cargoes within autophagosomes and subsequent delivery into lysosomes for degradation. Recently, we reported that S-acylation of SQSTM1 at the di-cysteine motif C289,290 directs SQSTM1 to lysosomes. We further showed that SQSTM1 S-acylation is significantly reduced in brains from both HD patients and mouse HD model, which may result in the cargo sequestration defect within autophagosomes in HD. Treatment with palmostatin B, a deacylation inhibitor, significantly increases SQSTM1 localization to lysosomes. Our work highlights SQSTM1 S-acylation as a novel potential therapeutic strategy in HD. As a crucial autophagy component, our work suggests S-acylation of SQSTM1 may have a broader role in neurodegeneration.https://www.tandfonline.com/doi/10.1080/27694127.2025.2547975AutophagyS-acylationpalmitoylationpalmostatin BHuntington diseasesequestosome 1
spellingShingle Y Alshehabi
F Abrar
D.D.O Martin
Sequestering sequestosome 1 via S-acylation in autophagy, Huntington disease, and beyond
Autophagy Reports
Autophagy
S-acylation
palmitoylation
palmostatin B
Huntington disease
sequestosome 1
title Sequestering sequestosome 1 via S-acylation in autophagy, Huntington disease, and beyond
title_full Sequestering sequestosome 1 via S-acylation in autophagy, Huntington disease, and beyond
title_fullStr Sequestering sequestosome 1 via S-acylation in autophagy, Huntington disease, and beyond
title_full_unstemmed Sequestering sequestosome 1 via S-acylation in autophagy, Huntington disease, and beyond
title_short Sequestering sequestosome 1 via S-acylation in autophagy, Huntington disease, and beyond
title_sort sequestering sequestosome 1 via s acylation in autophagy huntington disease and beyond
topic Autophagy
S-acylation
palmitoylation
palmostatin B
Huntington disease
sequestosome 1
url https://www.tandfonline.com/doi/10.1080/27694127.2025.2547975
work_keys_str_mv AT yalshehabi sequesteringsequestosome1viasacylationinautophagyhuntingtondiseaseandbeyond
AT fabrar sequesteringsequestosome1viasacylationinautophagyhuntingtondiseaseandbeyond
AT ddomartin sequesteringsequestosome1viasacylationinautophagyhuntingtondiseaseandbeyond